Advertisement

Platelet MAO-B activity in humans and stumptail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro 19-6327

  • R. Kettler
  • M. Da Prada
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Summary

MAO activity in platelets of six different animal species was compared with that of healthy volunteers. Only stumptail monkey (macaca arctoides) have similar high MAO-B and corresponding extremely low MAO-A activity in platelets as man. The highly selective, reversible inhibitor of MAO-B, Ro 19-6327, produced a marked and short-lasting inhibition of MAO-B in platelets of healthy volunteers as well as of stumptail monkey after oral administration. Therefore, platelets from stumptail monkey can adequately replace human platelets as model for the study of the pharmacological characteristics of MAO-B inhibitors.

Keywords

Platelet Rich Plasma Human Platelet Washed Platelet Macaca Arctoides Stumptail Monkey 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cesura AM, Imhof R, Takacs B, Galva MD, Picotti GB, Da Prada M (1988) [3H]Ro 16–6491, a selective probe for affinity labelling of monoamine oxidase type B in human brain and platelet membranes. J Neurochem 50: 1031–1043CrossRefGoogle Scholar
  2. Da Prada M, Kettler R, Keller HH, Burkard W (1988) Ro 19–6327: a reversible, highly selective inhibitor of type B monoamine oxidase completely devoid of tyramine potentiating effect. A comparison with selegiline. In: Proceedings of the 6th international catecholamine symposium. Raven Press (in press)Google Scholar
  3. Da Prada M, Kettler R, Keller HH, Kyburz E, Burkard WP (1987) Ro 196327: a novel highly selective and reversible MAO-B inhibitor. Acta Pharm Toxicol 60 [Suppl] 1: 10Google Scholar
  4. Da Prada M, Richards JG, Kettler R (1981) Amine storage organelles in platelets. In: Gordon G (ed) Platelets in biology and pathology. Elsevier/ North-Holland Biomedical PressGoogle Scholar
  5. Keller HH, Kettler R, Keller G, Da Prada M (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16–6491. Naunyn-Schmiedeberg’s Arch Pharmacol 335: 12–20PubMedCrossRefGoogle Scholar
  6. Murphy DL, Redmond DE, Baulu J, Donelly CH (1978) Platelet monoamine oxidase activity in 116 normal Rhesus monkeys: relations between enzyme activity and age, sex and genetic factors. Comp Biochem Physiol 60 C: 105–108Google Scholar
  7. Wise CD, Potkin SG, Bridge TP, Phelps BH, Cannon-Spoor HE, Wyatt RJ (1980) Sources of error in the determination of platelet monoamine oxidase: a review of methods. Schizophrenia Bull 6: 245–253Google Scholar
  8. Zimmer R, Kettler R, Bauer K, Thiede HM (1988) First pharmacological investigation in humans of Ro 19–6327, a new reversible and selective MAO-B inhibitor. In: Proceedings of the 9th international symposium on Parkinson’s disease, Jerusalem, Israel, June 5–9, 1988Google Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • R. Kettler
    • 1
  • M. Da Prada
    • 1
  1. 1.Pharmaceutical Research DepartmentF. Hoffmann-La Roche & Co., Ltd.BasleSwitzerland

Personalised recommendations